NasdaqGS:GILDBiotechs
Gilead Sciences (NasdaqGS:GILD) Reveals Promising Phase 3 Trial Results For Trodelvy In mTNBC
Gilead Sciences (NasdaqGS:GILD) recently announced positive results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, highlighting significant benefits in treating metastatic triple-negative breast cancer. This development may have supported the company's 12% price gain in the last quarter, complementing broader oncology advances. Despite a turbulent broader market impacted by global trade tension and inflationary pressures, Gilead's progress in clinical research, financial performance, and...